Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Ontario Clinical Oncology Group (OCOG)
University of Göttingen
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano